Clinical Trials

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

With key hires in finance, regulatory, and manufacturing, Cyllene Therapeutics signals it's preparing for the big leagues. But can it deliver?

A scientific breakthrough reveals a reversible cause for sarcopenia, offering the first real hope for a drug therapy to restore strength for millions of seniors.

Spryte Medical's novel nOCT system offers microscopic views inside brain vessels. With its pivotal clinical trial enrollment complete, it's a step closer to FDA approval.

Acclaimed scientist Michael Ehlers leaves big pharma's orbit for an AI startup. It's more than a career move; it's a test of whether technology can fix our broken drug development system.

SKNV's exclusive deal for a university-developed therapy shortens precancerous skin treatment to just four days, challenging norms in both patient care and pharmaceutical commercialization.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

Biotech firm ReBio Pharma appoints world-renowned expert Prof. Mandeep Sagoo as CMO, accelerating its novel RBP-01 therapy for uveal melanoma into the clinic.

D&D Pharmatech's zabopegdutide shows fast liver improvement independent of weight loss, a key differentiator in the crowded, multi-billion dollar MASH market.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

The new Aurora Research Network aims to replace guesswork with evidence-based protocols for severe neuropsychiatric crises. But can it unify a fragmented system?

At AIDS 2026, ViiV Healthcare unveils data challenging treatment norms, proving long-acting injectable efficacy, and paving the way for quarterly PrEP.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Shelf-stable donor milk pioneer Leche and testing firm Tiny Health launch a study to see if a little breast milk can make a big difference for formula-fed babies.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

Kolon TissueGene's revolutionary knee therapy, once a beacon of hope, fails a pivotal Phase 3 trial, raising questions about its future and the broader field.